Black cohosh
CAS 84776-26-1
Black cohosh (CAS 84776-26-1) is a pharmaceutical compound with 0 bioactivity targets and 138 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Black cohosh is linked to DTXSID2030857 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BLACK COHOSH | 236665 | SU | MTHSPL |
| Black Cohosh | 236665 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Black cohosh used for in pharmaceutical contexts?
Black cohosh (CAS 84776-26-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Black cohosh?
Black cohosh has 138 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Acute hepatic failure, Acute myocardial infarction, Anxiety, Aspartate aminotransferase increased, Asthenia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Black cohosh also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Black Cohosh Root Extract with EU status "permitted".
What clinical phase is Black cohosh in?
No phase 1-4 clinical development badge is rendered for Black cohosh because the matched compound identifier rows do not contain a max-phase value.